Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMRA

IMARA (IMRA) Stock Price, News & Analysis

IMARA logo

About IMARA Stock (NASDAQ:IMRA)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$6.32
$25.28
52-Week Range
N/A
Volume
271,700 shs
Average Volume
138,364 shs
Market Capitalization
$165.80 million
P/E Ratio
126.40
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Remove Ads
Receive IMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMARA and its competitors with MarketBeat's FREE daily newsletter.

IMRA Stock News Headlines

Imara Blume
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Imara 10% Owner Trades $336K In Company Stock
See More Headlines

IMRA Stock Analysis - Frequently Asked Questions

IMARA Inc. (NASDAQ:IMRA) announced its earnings results on Tuesday, November, 9th. The company reported ($2.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.64) by $1.44.

IMARA shares reverse split on Friday, February 24th 2023. The 1-4 reverse split was announced on Friday, February 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

IMARA (IMRA) raised $76 million in an IPO on Thursday, March 12th 2020. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Citigroup and SVB Leerink acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that IMARA investors own include NIO (NIO), Novavax (NVAX), NVIDIA (NVDA), Axsome Therapeutics (AXSM), Alibaba Group (BABA), AMC Entertainment (AMC) and BioXcel Therapeutics (BTAI).

Company Calendar

Last Earnings
11/09/2021
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMRA
Phone
N/A
Fax
N/A
Employees
41
Year Founded
N/A

Profitability

Trailing P/E Ratio
126.40
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.49 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
75.24
Book Value
$3.44 per share
Price / Book
N/A

Miscellaneous

Free Float
16,449,000
Market Cap
$165.80 million
Optionable
Not Optionable
Beta
1.09
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:IMRA) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners